Trevi Therapeutics Inc (TRVI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Trevi Therapeutics Inc (TRVI) has a cash flow conversion efficiency ratio of -0.057x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.88 Million) by net assets ($189.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Trevi Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Trevi Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read TRVI current and long-term liabilities for a breakdown of total debt and financial obligations.
Trevi Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Trevi Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Afry AB
ST:AFRY
|
-0.006x |
|
Opera Limited
F:2V8
|
0.043x |
|
Maze Therapeutics, Inc. Common Stock
NASDAQ:MAZE
|
-0.078x |
|
Blackrock Innovation & Growth Trust
NYSE:BIGZ
|
N/A |
|
Snowsky Salt Industry Group Co Ltd
SHG:600929
|
0.020x |
|
Chemtrade Logistics Income Fund
TO:CHE-UN
|
0.206x |
|
Cogeco Communications Inc
TO:CCA
|
0.046x |
|
Orange Belgium SA
BR:OBEL
|
0.124x |
Annual Cash Flow Conversion Efficiency for Trevi Therapeutics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Trevi Therapeutics Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Trevi Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $99.64 Million | $-38.26 Million | -0.384x | +0.06% |
| 2023-12-31 | $82.55 Million | $-31.71 Million | -0.384x | -46.51% |
| 2022-12-31 | $107.46 Million | $-28.18 Million | -0.262x | +84.53% |
| 2021-12-31 | $17.07 Million | $-28.95 Million | -1.695x | -59.48% |
| 2020-12-31 | $27.28 Million | $-29.00 Million | -1.063x | -151.07% |
| 2019-12-31 | $54.55 Million | $-23.09 Million | -0.423x | +59.94% |
| 2018-12-31 | $17.31 Million | $-18.29 Million | -1.057x | -95.84% |
| 2017-12-31 | $14.78 Million | $-7.97 Million | -0.540x | -183.95% |
| 2016-12-31 | $-17.41 Million | $-11.19 Million | 0.643x | -- |
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is … Read more